Real-World Evidence (RWE)

Real-World Evidence (RWE) refers to clinical insights derived from analysis of real-world data, encompassing information collected outside traditional clinical trial settings during routine healthcare delivery. This evidence complements randomised trial findings by capturing therapeutic performance in diverse, unselected patient populations under actual practice conditions, increasingly influencing regulatory decisions, reimbursement determinations, and clinical guideline development.

Real-world data sources include electronic health records, claims databases, patient registries, wearable devices, and mobile health applications, collectively providing comprehensive views of treatment patterns, outcomes, and healthcare utilisation. Analysing these large, longitudinal datasets reveals insights unavailable from controlled trials including long-term safety signals, comparative effectiveness across treatment options, and real-world adherence patterns. Advanced analytics including propensity score matching help address confounding inherent in observational data. Regulatory agencies including the FDA have issued frameworks for using RWE to support label expansions and fulfil post-marketing requirements. Companies leverage RWE to optimise clinical trial designs, identify appropriate patient populations, and generate health economics data. Payers increasingly require RWE demonstrating real-world value as part of reimbursement negotiations. As healthcare becomes increasingly digitised, RWE will play an expanding role in evidence generation complementing traditional research methodologies.